Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. – UroToday
|
Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
UroToday Bacillus Calmette-Guérin in urothelial carcinoma, high-dose interleukin-2 in renal cell carcinoma, and sipuleucel-T in prostate cancer serve as enduring examples that the host immune response can be harnessed to promote effective anti-tumor immunity in … |
